ImmunoPrecise Antibodies, Ltd. (NASDAQ: IPA) is engaged as an innovative technology company, which is designed to research and develop novel antibody treatments against a range of diseases. Shares of the biotech company are skyrocketing 131% through afternoon trading on Thursday, July 22, 2021. Over the past three months, ImmunoPrecise has seen average daily volume of 51,820 shares. However, volume of 86.03 million shares or dollar volume of $1.11 billion, has already exchanged hands through afternoon trading on Thursday.
Shares of ImmunoPrecise Antibodies have more than doubled on the day, after the company released testing results of its TATX-03 PolyTope therapy, a four monoclonal antibody cocktail developed for the treatment of COVID. The initial results showed that TATX-03 provided “potent pseudovirus neutralizing activity” against the Delta variant (B.1.617.2) of the coronavirus. ImmunoPrecise had previously announced that TATX-03 showed strong ability to reduce the viral load of the Alpha (B.1.1.7) and Beta (B.1.351) variants in vitro.
ImmunoPrecise Monoclonal Cocktail Shows Promise in Battle Against Delta
The biotech company has been working on its PolyTope cocktail for some time, as a potential tool to fight the emerging COVID variants of concern. As such, management says they have continued to monitor progress and efficacy in emerging new variants. Given the binding capabilities of the Delta variant, ImmunoPrecise was able to determine similarities to other variants of concern (Alpha, Beta, Gamma). As a result to the binding data and the neutralizing properties of its TATX-03 cocktail, management believes its monoclonal treatment “will be functionally less prone to escapes-by-one mutations.”
“The data from IPA’s screenings on the variants of concern speak to the importance of targeting diversified epitopes on the spike trimer for treatment sustainability and resilience of our PolyTope cocktail,” stated Dr. Ilse Roodink, IPA’s Chief Scientific Officer and Global Program Director for COVID Research. “Our TATX-03 cocktail is rationally designed for broad epitope coverage relying on multiple antibodies, which have shown in pre-clinical studies to work synergistically together, to reduce the risk of mutagenic escape, and have the potential to reduce the risk of new variants. We believe this strategy of multi-antibody cocktails is more crucial now with the surge of new variants of concern and breakthrough cases.”
ImmunoPrecise Antibodies’ results come at a critical time in the global battle against coronavirus. The Delta variant is now the main variant spreading across much of the world. Positive COVID tests, hospitalizations, and even deaths have continued to climb in recent weeks, as vaccination efforts wane.
Disclosure: Neither Matt Rego nor Spotlight Growth have any position or relationship with any companies mentioned in this article. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.